Equities research analysts at Stifel Nicolaus started coverage on shares of Viveve Medical (NASDAQ:VIVE) in a report issued on Tuesday. The firm set a “buy” rating and a $6.00 price target on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 78.57% from the company’s current price.
Several other analysts have also recently issued reports on VIVE. ValuEngine cut Viveve Medical from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Northland Securities started coverage on Viveve Medical in a report on Friday, January 5th. They set an “outperform” rating and a $8.00 price target for the company. Mizuho reiterated a “buy” rating and set a $10.00 price target on shares of Viveve Medical in a report on Friday, January 5th. Ladenburg Thalmann reiterated a “buy” rating on shares of Viveve Medical in a report on Thursday, January 4th. Finally, Maxim Group reiterated a “buy” rating and set a $11.00 price target on shares of Viveve Medical in a report on Friday, March 16th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $9.43.
Shares of NASDAQ:VIVE opened at $3.36 on Tuesday. The company has a debt-to-equity ratio of -11.13, a current ratio of 3.41 and a quick ratio of 3.16. The firm has a market capitalization of $94.01, a price-to-earnings ratio of -1.59 and a beta of -0.48. Viveve Medical has a 52-week low of $2.96 and a 52-week high of $11.16.
Viveve Medical (NASDAQ:VIVE) last issued its earnings results on Thursday, March 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.06). The company had revenue of $5.10 million during the quarter, compared to analysts’ expectations of $5.09 million. Viveve Medical had a negative net margin of 241.75% and a negative return on equity of 328.38%. equities analysts expect that Viveve Medical will post -1.44 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in VIVE. State Street Corp purchased a new position in Viveve Medical during the 2nd quarter valued at about $1,282,000. California State Teachers Retirement System purchased a new position in Viveve Medical during the 2nd quarter valued at about $190,000. Neuberger Berman Group LLC purchased a new position in Viveve Medical during the 3rd quarter valued at about $419,000. ING Groep NV boosted its holdings in Viveve Medical by 7.7% during the 4th quarter. ING Groep NV now owns 350,000 shares of the company’s stock valued at $1,740,000 after acquiring an additional 25,000 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in Viveve Medical by 135.1% during the 4th quarter. Wells Fargo & Company MN now owns 37,727 shares of the company’s stock valued at $188,000 after acquiring an additional 21,683 shares during the period. Institutional investors and hedge funds own 40.19% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/17/viveve-medical-vive-now-covered-by-analysts-at-stifel-nicolaus.html.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.